Overview
- Voters, in a Fabrizio Ward/Market Institute poll released Tuesday, say they are more likely to back candidates who push earlier diagnosis and easier access to Alzheimer’s treatments.
- Support for the Alzheimer’s Screening and Prevention (ASAP) Act reaches about 92%, with the bill allowing Medicare to cover future FDA‑cleared blood tests that screen for Alzheimer’s.
- Eighty‑nine percent say Medicare and private insurers block or delay access to FDA‑approved tests and treatments, reflecting broad frustration with coverage hurdles.
- Poll analysts describe a campaign opening for GOP candidates, noting strong resonance in swing states such as Florida, North Carolina, Ohio, and Pennsylvania.
- A Michigan patient’s case reported by the Washington Examiner shows how a change in insurance cut off an FDA‑approved therapy that had been helping, highlighting real‑world stakes for families.